Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 174

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

BAP1 mutations in high-grade meningioma: implications for patient care

Open access
Shankar, Ganesh M, Santagata, Sandro · 2017 · Neuro-Oncology

Abstract

We have recently shown that the breast cancer (BRCA)1-associated protein-1 tumor suppressor gene (BAP1) is inactivated in a subset of clinically aggressive meningiomas that display rhabdoid histomorphology. Immunohistochemistry for BAP1 protein provides a rapid and inexpensive method for screening suspected cases. Notably, some patients with BAP1-mutant meningiomas have germline BAP1 mutations and BAP1 tumor predisposition syndrome (TPDS). It appears that nearly all patients with germline BAP1 mutations develop malignancies by age 55, most frequently uveal melanoma, cutaneous melanoma, pleural or peritoneal malignant mesothelioma, or renal cell carcinoma, although other cancers have also been associated with BAP1 TPDS. Therefore, when confronted with a patient with a potentially high-grade rhabdoid meningioma, it is important that neuropathologists assess the BAP1 status of the tumor and that the patient's family history of cancer is carefully ascertained. In the appropriate clinical setting, genetic counseling and germline BAP1 DNA sequencing should be performed. A cancer surveillance program for individuals who carry germline BAP1 mutations may help identify tumors such as uveal melanoma, cutaneous melanoma, and renal cell carcinoma at early and treatable stages. Because BAP1-mutant meningiomas are rare tumors, multi-institutional efforts will be needed to evaluate therapeutic strategies and to further define the clinicopathologic features of these tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/neuonc/nox094

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 87

  1. 2017, Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas, Neuro Oncol, 19, 535
  2. 2017, SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas, Neuro Oncol, 19, 345
  3. 2013, Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations, Nat Genet, 45, 285, 10.1038/ng.2526 · DOI · Paper page
  4. 2013, Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO, Science, 339, 1077, 10.1126/science.1233009 · DOI · Paper page
  5. 2016, Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas, Nat Genet, 48, 1253, 10.1038/ng.3651 · DOI · Paper page
  6. 2016, Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma, Neuro Oncol, 18, 649, 10.1093/neuonc/nov316 · DOI · Paper page
  7. 2013, Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations, Acta Neuropathol, 125, 351, 10.1007/s00401-013-1093-x · DOI · Paper page
  8. 2014, Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5, Oncotarget, 5, 10596, 10.18632/oncotarget.2517 · DOI
  9. 2017, Integrated genomic analyses of de novo pathways underlying atypical meningiomas, Nat Commun, 8, 14433, 10.1038/ncomms14433 · DOI · Paper page
  10. 2002, A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas, Brain Pathol, 12, 183, 10.1111/j.1750-3639.2002.tb00433.x · doi:10.1111/j.1750-3639.2002.tb00433.x
  11. 2015, ARID1A and TERT promoter mutations in dedifferentiated meningioma, Cancer Genet, 208, 345, 10.1016/j.cancergen.2015.03.005 · DOI
  12. 2014, High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression, Brain Pathol, 24, 184, 10.1111/bpa.12110 · DOI · Paper page
  13. 2016, TERT promoter mutations and risk of recurrence in meningioma, J Natl Cancer Inst, 108
  14. 2016, Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539, Neuro Oncol, 18, 565, 10.1093/neuonc/nov247 · DOI
  15. 2016, A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma, Neuro Oncol, 18, 269, 10.1093/neuonc/nov177 · DOI
  16. 2015, Better see to better agree: phosphohistone H3 increases interobserver agreement in mitotic count for meningioma grading and imposes new specific thresholds, Neuro Oncol, 17, 663, 10.1093/neuonc/nov002 · doi:10.1093/neuonc/nov002
  17. 2017, Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community, Neuro Oncol, 19, 336
  18. 2016, Predicting outcome of epilepsy after meningioma resection, Neuro Oncol, 18, 1002, 10.1093/neuonc/nov303 · DOI
  19. 2016, Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological grade, Neuro Oncol, 18, 863, 10.1093/neuonc/nov285 · DOI
  20. 2016, Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma, Neuro Oncol, 18, 401, 10.1093/neuonc/nov183 · doi:10.1093/neuonc/nov183
  21. 2015, Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma, Neuro Oncol, 17, 116, 10.1093/neuonc/nou148 · DOI · Paper page
  22. 1993, Germline deletion in a neurofibromatosis type 2 kindred inactivates the NF2 gene and a candidate meningioma locus, Hum Mol Genet, 2, 1215, 10.1093/hmg/2.8.1215 · doi:10.1093/hmg/2.8.1215
  23. 2014, Germline SMARCE1 mutations predispose to both spinal and cranial clear cell meningiomas, J Pathol, 234, 436, 10.1002/path.4427 · doi:10.1002/path.4427
  24. 2013, Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas, Nat Genet, 45, 295, 10.1038/ng.2552 · DOI · Paper page
  25. 2011, Germline SMARCB1 mutation and somatic NF2 mutations in familial multiple meningiomas, J Med Genet, 48, 93, 10.1136/jmg.2010.082420 · DOI
  26. 2010, Schwannomatosis associated with multiple meningiomas due to a familial SMARCB1 mutation, Neurogenetics, 11, 73, 10.1007/s10048-009-0204-2 · doi:10.1007/s10048-009-0204-2
  27. 2011, Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers, J Med Genet, 48, 856, 10.1136/jmedgenet-2011-100156 · DOI · Paper page
  28. 2015, Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction, Cancer Lett, 369, 261, 10.1016/j.canlet.2015.09.011 · DOI
  29. 2015, A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma, Clin Genet, 88, 267, 10.1111/cge.12501 · DOI
  30. 2015, Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States, Neuro Oncol, 17, 1166, 10.1093/neuonc/nov069 · doi:10.1093/neuonc/nov069
  31. 2016, Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010, Neuro Oncol
  32. 1998, “Rhabdoid” meningioma: an aggressive variant, Am J Surg Pathol, 22, 1482, 10.1097/00000478-199812000-00005 · doi:10.1097/00000478-199812000-00005
  33. 2016, Meningiomas with rhabdoid features lacking other histologic features of malignancy: a study of 44 cases and review of the literature, J Neuropathol Exp Neurol, 75, 44, 10.1093/jnen/nlv006 · DOI
  34. 2016, Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations, Nat Genet, 48, 407, 10.1038/ng.3520 · DOI · Paper page
  35. 2010, Frequent mutation of BAP1 in metastasizing uveal melanomas, Science, 330, 1410, 10.1126/science.1194472 · DOI · Paper page
  36. 2011, Germline BAP1 mutations predispose to malignant mesothelioma, Nat Genet, 43, 1022, 10.1038/ng.912 · DOI · Paper page
  37. 2015, Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases, Lung Cancer, 87, 77, 10.1016/j.lungcan.2014.10.017 · DOI
  38. 2016, Gender-specific molecular and clinical features underlie malignant pleural mesothelioma, Cancer Res, 76, 319, 10.1158/0008-5472.CAN-15-0751 · DOI
  39. 2014, Recent developments in prognostic and predictive testing in uveal melanoma, Curr Opin Ophthalmol, 25, 234, 10.1097/ICU.0000000000000051 · DOI · Paper page
  40. 2012, Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families, PLoS One, 7, e35295, 10.1371/journal.pone.0035295 · DOI · Paper page
  41. 2013, A BAP1 mutation in a Danish family predisposes to uveal melanoma and other cancers, PLoS One, 8, e72144, 10.1371/journal.pone.0072144 · DOI
  42. 2015, Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival, Carcinogenesis, 36, 76, 10.1093/carcin/bgu227 · DOI · Paper page
  43. 2016, Consensus report of the 2015 Weinman International Conference on Mesothelioma, J Thorac Oncol, 11, 1246, 10.1016/j.jtho.2016.04.028 · DOI
  44. 2013, Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations, J Thorac Oncol, 8, 1430, 10.1097/JTO.0b013e31829e7ef9 · DOI
  45. 2016, The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma, Mod Pathol, 29, 14, 10.1038/modpathol.2015.121 · DOI
  46. 2009, Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi, Nature, 457, 599, 10.1038/nature07586 · DOI · Paper page
  47. 2010, Mutations in GNA11 in uveal melanoma, N Engl J Med, 363, 2191, 10.1056/NEJMoa1000584 · DOI · Paper page
  48. 2016, Driver mutations in uveal melanoma: associations with gene expression profile and patient outcomes, JAMA Ophthalmol, 134, 728, 10.1001/jamaophthalmol.2016.0903 · DOI · Paper page
  49. 2015, Loss of BAP1 function leads to EZH2-dependent transformation, Nat Med, 21, 1344, 10.1038/nm.3947 · DOI · Paper page
  50. 2017, DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis, Lancet Oncol
  51. 2017, Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma, Acta Neuropathol, 133, 431, 10.1007/s00401-017-1678-x · DOI · Paper page
  52. 2015, High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma, J Thorac Oncol, 10, 565, 10.1097/JTO.0000000000000471 · DOI · Paper page
  53. 2016, Comparing the prognostic value of BAP1 mutation pattern, chromosome 3 status, and BAP1 immunohistochemistry in uveal melanoma, Am J Surg Pathol, 40, 796, 10.1097/PAS.0000000000000645 · DOI
  54. 2013, Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC, Epigenetics, 8, 486, 10.4161/epi.24552 · DOI
  55. 2017, Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy, Neuro Oncol, 19, 699
  56. 2017, Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors, Neuro Oncol
  57. 2014, Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma, Mod Pathol, 27, 1321, 10.1038/modpathol.2014.43 · DOI · Paper page
  58. 2015, Combined genetic and genealogic studies uncover a large BAP1 cancer syndrome kindred tracing back nine generations to a common ancestor from the 1700s, PLoS Genet, 11, e1005633, 10.1371/journal.pgen.1005633 · DOI
  59. 2013, Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma, Cancer Genet, 206, 206, 10.1016/j.cancergen.2013.05.018 · DOI
  60. 2012, Toward an improved definition of the tumor spectrum associated with BAP1 germline mutations, J Clin Oncol, 30, e337, 10.1200/JCO.2011.41.2965 · DOI
  61. 2012, A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression, Am J Surg Pathol, 36, 818, 10.1097/PAS.0b013e3182498be5 · DOI · Paper page
  62. 2012, BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs, J Transl Med, 10, 179, 10.1186/1479-5876-10-179 · DOI · Paper page
  63. 2015, Analysis of BAP1 germline gene mutation in young uveal melanoma patients, Ophthalmic Genet, 36, 126, 10.3109/13816810.2015.1010734 · DOI
  64. 2012, A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma, Pigment Cell Melanoma Res, 25, 815, 10.1111/pcmr.12006 · DOI
  65. 2014, Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic sequestration mediated by the atypical ubiquitin ligase UBE2O, Mol Cell, 54, 392, 10.1016/j.molcel.2014.03.002 · DOI · Paper page
  66. 2012, Loss of the tumor suppressor BAP1 causes myeloid transformation, Science, 337, 1541, 10.1126/science.1221711 · DOI · Paper page
  67. 2002, Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains, EMBO J, 21, 6755, 10.1093/emboj/cdf691 · DOI · Paper page
  68. 2009, Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia, Br J Haematol, 145, 788, 10.1111/j.1365-2141.2009.07697.x · DOI · Paper page
  69. 2016, Bap1 is a bona fide tumor suppressor: genetic evidence from mouse models carrying heterozygous germline Bap1 mutations, Cancer Res, 76, 2836, 10.1158/0008-5472.CAN-15-3371 · DOI
  70. 2016, Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma, Oncogene, 35, 1996, 10.1038/onc.2015.243 · DOI · Paper page
  71. 2012, Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma, Cancer Sci, 103, 868, 10.1111/j.1349-7006.2012.02223.x · DOI · Paper page
  72. 2015, BAP1 missense mutation c.2054 A>T (p.E685V) completely disrupts normal splicing through creation of a novel 5ʹ splice site in a human mesothelioma cell line, PLoS One, 10, e0119224, 10.1371/journal.pone.0119224 · DOI
  73. 2015, Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cells, Cancer Sci, 106, 990, 10.1111/cas.12698 · DOI
  74. 2016, A tumor-specific neo-antigen caused by a frameshift mutation in BAP1 is a potential personalized biomarker in malignant peritoneal mesothelioma, Int J Mol Sci, 17
  75. 2012, Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma, Clin Cancer Res, 18, 408, 10.1158/1078-0432.CCR-11-0946 · DOI · Paper page
  76. 2015, Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial, Lancet Oncol, 16, 447, 10.1016/S1470-2045(15)70056-2 · DOI · Paper page
  77. 2014, Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial, JAMA, 311, 2397, 10.1001/jama.2014.6096 · DOI · Paper page
  78. 2016, Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status, Nat Med, 22, 577, 10.1038/nm.4098 · DOI
  79. 2016, Reply to “Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status”, Nat Med, 22, 578, 10.1038/nm.4094 · DOI
  80. 2014, Germline mutations in BAP1 impair its function in DNA double-strand break repair, Cancer Res, 74, 4282, 10.1158/0008-5472.CAN-13-3109 · DOI · Paper page
  81. 2012, BAP1 loss defines a new class of renal cell carcinoma, Nat Genet, 44, 751, 10.1038/ng.2323 · DOI · Paper page
  82. 2016, Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases, Clin Genet, 89, 285, 10.1111/cge.12630 · DOI · Paper page
  83. 2015, Clinical characteristics of uveal melanoma in patients with germline BAP1 mutations, JAMA Ophthalmol, 133, 881, 10.1001/jamaophthalmol.2015.1119 · DOI
  84. 2016, BRCA1-associated protein 1 (BAP1) immunohistochemical expression as a diagnostic tool in malignant pleural mesothelioma classification: a large retrospective study, J Thorac Oncol, 11, 2006, 10.1016/j.jtho.2016.06.020 · DOI
  85. 2017, A population-based analysis of germline BAP1 mutations in melanoma, Hum Mol Genet
  86. 2011, Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma, Nat Genet, 44, 17, 10.1038/ng.1014 · DOI · Paper page
  87. 2013, Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas, Nat Genet, 45, 1470, 10.1038/ng.2813 · DOI · Paper page

Cited by

See all 174

Metadata

Authors
Shankar, G. M., & Santagata, S.
Venue
Neuro-Oncology
Published
2017-05-08
Volume
19
Issue
11
Pages
1447-1456
ISSN
  • 1522-8517 (ISSN-L)
  • 1523-5866
OpenAlex
W2612865792
Cited by
174
References
3
FWCI
11.13
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BAP1 mutations in high-grade meningioma: implications for patient care. https://app.cochat.ai/papers/10.1093/neuonc/nox094
The paper
Shankar, G. M., & Santagata, S. (2017). BAP1 mutations in high-grade meningioma: implications for patient care. Neuro-Oncology. https://doi.org/10.1093/neuonc/nox094

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.